Pooled venous thromboembolism (VTE) rates among thalidomide- and lenolidomide-treated patients with multiple myeloma.
| . | . | % (95% Confidence Interval) [No. patients with VTE/total no. of patients treated with regimen] . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| . | . | Monotherapy . | Dexmethasone ±chemotherapy . | Dexam/ethasone and doxorubicin ±chemotherapy . | Melphalan and prednisone ±chemotherapy . | ||||
| . | Prophylaxis . | Thalidomide (n=986) . | Lenalidomide (n=324) . | Thalidomide (n=1544) . | Lenalidomide (n=712) . | Thalidomide (n=1137) . | Lenalidomide (n=0) . | Thalidomide (n=351) . | Lenalidomide (n=24) . |
| Abbreviations: INR, international normalized ratio; LMWH, low-molecular-weight heparin. Adapted from Bennet CL et al.57 | |||||||||
| Not previously treated | None | 3 (0–6) [2/73] | 2 (0.1–4) [4/222] | 14 (11–16) [109/795] | 14 (10–18) [38/278] | 24 (21–28) [148/610] | — | 15 (11–19) [43/287] | — |
| Warfarin, low dose | — | — | 15 (9–21) [18/121] | — | — | — | — | — | |
| INR 2–3 or LMWH | — | — | 0 [0/63] | — | 9 (5–13) [19/211] | — | 3 (0–7) [2/64] | — | |
| Aspirin | — | — | — | 11 (5–18) [10/88] | 7 (0–14) [3/45] | — | — | 4 (0–12) [1/24] | |
| Relapsed/refractory | None | 3 (2–4) [23/913] | 0 [0/102] | 6 (3–8) [25/454] | 24 (20–29) [84/346] | 17 (13–22) [47/271] | — | — | — |
| . | . | % (95% Confidence Interval) [No. patients with VTE/total no. of patients treated with regimen] . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| . | . | Monotherapy . | Dexmethasone ±chemotherapy . | Dexam/ethasone and doxorubicin ±chemotherapy . | Melphalan and prednisone ±chemotherapy . | ||||
| . | Prophylaxis . | Thalidomide (n=986) . | Lenalidomide (n=324) . | Thalidomide (n=1544) . | Lenalidomide (n=712) . | Thalidomide (n=1137) . | Lenalidomide (n=0) . | Thalidomide (n=351) . | Lenalidomide (n=24) . |
| Abbreviations: INR, international normalized ratio; LMWH, low-molecular-weight heparin. Adapted from Bennet CL et al.57 | |||||||||
| Not previously treated | None | 3 (0–6) [2/73] | 2 (0.1–4) [4/222] | 14 (11–16) [109/795] | 14 (10–18) [38/278] | 24 (21–28) [148/610] | — | 15 (11–19) [43/287] | — |
| Warfarin, low dose | — | — | 15 (9–21) [18/121] | — | — | — | — | — | |
| INR 2–3 or LMWH | — | — | 0 [0/63] | — | 9 (5–13) [19/211] | — | 3 (0–7) [2/64] | — | |
| Aspirin | — | — | — | 11 (5–18) [10/88] | 7 (0–14) [3/45] | — | — | 4 (0–12) [1/24] | |
| Relapsed/refractory | None | 3 (2–4) [23/913] | 0 [0/102] | 6 (3–8) [25/454] | 24 (20–29) [84/346] | 17 (13–22) [47/271] | — | — | — |